196 related articles for article (PubMed ID: 37543577)
1. Spatial tumour gene signature discriminates neoplastic from non-neoplastic compartments in colon cancer: unravelling predictive biomarkers for relapse.
Sallinger K; Gruber M; Müller CT; Bonstingl L; Pritz E; Pankratz K; Gerger A; Smolle MA; Aigelsreiter A; Surova O; Svedlund J; Nilsson M; Kroneis T; El-Heliebi A
J Transl Med; 2023 Aug; 21(1):528. PubMed ID: 37543577
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
3. A stroma-related lncRNA panel for predicting recurrence and adjuvant chemotherapy benefit in patients with early-stage colon cancer.
Zhou R; Sun H; Zheng S; Zhang J; Zeng D; Wu J; Huang Z; Rong X; Bin J; Liao Y; Shi M; Liao W
J Cell Mol Med; 2020 Mar; 24(5):3229-3241. PubMed ID: 31989761
[TBL] [Abstract][Full Text] [Related]
4. A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I-III colon cancer.
Zhou R; Zeng D; Zhang J; Sun H; Wu J; Li N; Liang L; Shi M; Bin J; Liao Y; Huang N; Liao W
EBioMedicine; 2019 Apr; 42():420-430. PubMed ID: 30917936
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients.
Giampieri R; Scartozzi M; Loretelli C; Piva F; Mandolesi A; Lezoche G; Del Prete M; Bittoni A; Faloppi L; Bianconi M; Cecchini L; Guerrieri M; Bearzi I; Cascinu S
PLoS One; 2013; 8(9):e72843. PubMed ID: 24023782
[TBL] [Abstract][Full Text] [Related]
6. A DNA methylation signature for the prediction of tumour recurrence in stage II colorectal cancer.
Li M; Zhu C; Xue Y; Miao C; He R; Li W; Zhang B; Yu W; Huang X; Lv M; Xu Y; Huang Q
Br J Cancer; 2023 May; 128(9):1681-1689. PubMed ID: 36828869
[TBL] [Abstract][Full Text] [Related]
7. [K-ras mutational status and tumour-infiltrating lymphocytes in human colon cancer: state of the art and future perspectives].
Kocián P; Sedivcová M; Drgáč J; Cerná K; Hoch J; Kodet R; Bartůňková J; Spíšek R; Fialová A
Rozhl Chir; 2012 Aug; 91(8):427-32. PubMed ID: 23153426
[TBL] [Abstract][Full Text] [Related]
8. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
10. Confirmation of a metastasis-specific microRNA signature in primary colon cancer.
Coebergh van den Braak RRJ; Sieuwerts AM; Lalmahomed ZS; Smid M; Wilting SM; Bril SI; Xiang S; van der Vlugt-Daane M; de Weerd V; van Galen A; Biermann K; van Krieken JHJM; Kloosterman WP; Foekens JA; ; Martens JWM; IJzermans JNM
Sci Rep; 2018 Mar; 8(1):5242. PubMed ID: 29588449
[TBL] [Abstract][Full Text] [Related]
11. Recent approaches to identifying biomarkers for high-risk stage II colon cancer.
Akiyoshi T; Kobunai T; Watanabe T
Surg Today; 2012 Nov; 42(11):1037-45. PubMed ID: 22961195
[TBL] [Abstract][Full Text] [Related]
12. A 15-gene signature for prediction of colon cancer recurrence and prognosis based on SVM.
Xu G; Zhang M; Zhu H; Xu J
Gene; 2017 Mar; 604():33-40. PubMed ID: 27998790
[TBL] [Abstract][Full Text] [Related]
13. Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer.
Jiang Y; Casey G; Lavery IC; Zhang Y; Talantov D; Martin-McGreevy M; Skacel M; Manilich E; Mazumder A; Atkins D; Delaney CP; Wang Y
J Mol Diagn; 2008 Jul; 10(4):346-54. PubMed ID: 18556775
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment derived signature predicting relapse-free survival in I-III cancer and preliminary experiment verification.
Zhang Z; Wu Q; Zhu D; He G; Feng Q; Xu J
Int Immunopharmacol; 2021 Feb; 91():107243. PubMed ID: 33321467
[TBL] [Abstract][Full Text] [Related]
15. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
[TBL] [Abstract][Full Text] [Related]
16. LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival.
Torres S; Garcia-Palmero I; Herrera M; Bartolomé RA; Peña C; Fernandez-Aceñero MJ; Padilla G; Peláez-García A; Lopez-Lucendo M; Rodriguez-Merlo R; García de Herreros A; Bonilla F; Casal JI
Clin Cancer Res; 2015 Nov; 21(21):4892-902. PubMed ID: 26206869
[TBL] [Abstract][Full Text] [Related]
17. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer.
Lai YH; Wu LC; Li PS; Wu WH; Yang SB; Xia P; He XX; Xiao LB
Colorectal Dis; 2014 Apr; 16(4):259-64. PubMed ID: 24118729
[TBL] [Abstract][Full Text] [Related]
18. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
19. Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.
Stotz M; Herzog SA; Pichler M; Smolle M; Riedl J; Rossmann C; Bezan A; Stöger H; Renner W; Berghold A; Gerger A
Anticancer Res; 2017 Apr; 37(4):2011-2018. PubMed ID: 28373475
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer.
Mo S; Dai W; Xiang W; Li Y; Feng Y; Zhang L; Li Q; Cai G
Carcinogenesis; 2019 Jul; 40(7):861-870. PubMed ID: 30933267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
